Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Page 1
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
In an 8-week, phase 2 trial, sparsentan, a dual endothelin-angiotensin receptor antagonist, reduced proteinuria in patients with FSGS. The efficacy and safety of longer-term treatment with sparsentan for FSGS are unknown. METHODS: In this phase 3 trial, we enrolled patient …
In an 8-week, phase 2 trial, sparsentan, a dual endothelin-angiotensin receptor antagonist, reduced proteinuria in patients with FSGS. The e …
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term nephroprotective potential of sparsentan. FUNDING: Travere Therapeutics....
Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term …
Association Between Maintenance Immunosuppressive Regimens and COVID-19 Mortality in Kidney Transplant Recipients.
Gérard AO, Barbosa S, Anglicheau D, Couzi L, Hazzan M, Thaunat O, Blancho G, Caillard S, Sicard A; French SOT COVID Registry. Gérard AO, et al. Transplantation. 2022 Oct 1;106(10):2063-2067. doi: 10.1097/TP.0000000000004254. Epub 2022 Jul 27. Transplantation. 2022. PMID: 35883236 Free PMC article.
CONCLUSIONS: Corticosteroid-free regimens were associated with a lower risk of death in KT recipients with COVID-19. Long-term exposure to corticosteroids impairs immune functions and may predispose solid organ transplant recipients to severe forms of COVID-19....
CONCLUSIONS: Corticosteroid-free regimens were associated with a lower risk of death in KT recipients with COVID-19. Long-term exposu …
Belatacept-based immunosuppressive regimen in HIV-positive kidney transplant recipients.
El Sakhawi K, Melica G, Scemla A, Bertrand D, Garrouste C, Malvezzi P, Rémy P, Moktefi A, Ingels A, Champy C, Lelièvre JD, Kheav D, Morel A, Mokrani D, Attias P, Grimbert P, Matignon M. El Sakhawi K, et al. Among authors: garrouste c. Clin Kidney J. 2020 Dec 16;14(8):1908-1914. doi: 10.1093/ckj/sfaa231. eCollection 2021 Aug. Clin Kidney J. 2020. PMID: 34345414 Free PMC article.
BACKGROUND: Kidney allograft survival in human immunodeficiency virus (HIV)-positive patients is lower than that in the general population. Belatacept increases long-term patient and allograft survival rates when compared with calcineurin inhibitors (CNIs). ...CONCLUSIONS: …
BACKGROUND: Kidney allograft survival in human immunodeficiency virus (HIV)-positive patients is lower than that in the general population. …
Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults.
Barbour T, Scully M, Ariceta G, Cataland S, Garlo K, Heyne N, Luque Y, Menne J, Miyakawa Y, Yoon SS, Kavanagh D; 311 Study Group Members. Barbour T, et al. Kidney Int Rep. 2021 Mar 24;6(6):1603-1613. doi: 10.1016/j.ekir.2021.03.884. eCollection 2021 Jun. Kidney Int Rep. 2021. PMID: 34169200 Free PMC article.
METHODS: The aim of this analysis was to characterize the long-term efficacy and the safety profile of ravulizumab in adults with aHUS who had completed the initial evaluation period of the trial. ...CONCLUSION: This analysis reveals that ravulizumab administered every 8 w …
METHODS: The aim of this analysis was to characterize the long-term efficacy and the safety profile of ravulizumab in adults with aHU …
Results of a nation-wide cohort study suggest favorable long-term outcomes of clone-targeted chemotherapy in immunotactoid glomerulopathy.
Javaugue V, Dufour-Nourigat L, Desport E, Sibille A, Moulin B, Bataille P, Bindi P, Garrouste C, Mariat C, Karlin L, Nouvier M, Goujon JM, Gnemmi V, Fermand JP, Touchard G, Bridoux F. Javaugue V, et al. Among authors: garrouste c. Kidney Int. 2021 Feb;99(2):421-430. doi: 10.1016/j.kint.2020.06.039. Epub 2020 Jul 30. Kidney Int. 2021. PMID: 32739419
Immunotactoid glomerulopathy is a rare disease defined by glomerular microtubular immunoglobulin deposits. Since management and long-term outcomes remain poorly described, we retrospectively analyzed results of 27 adults from 21 departments of nephrology in France accrued …
Immunotactoid glomerulopathy is a rare disease defined by glomerular microtubular immunoglobulin deposits. Since management and long-term …
Temporal trends in living kidney donation in France between 2007 and 2017.
Gaillard F, Jacquemont L, Roberts V, Albano L, Allard J, Bouvier N, Buchler M, Titeca-Beauport D, Couzi L, Delahousse M, Ducloux D, Durrbach A, Etienne I, Frimat L, Garrouste C, Grimbert P, Hazzan M, Hertig A, Kamar N, Quintrec ML, Mariat C, Moal V, Moulin B, Mousson C, Pouteil-Noble C, Rieu P, Rostaing L, Thierry A, Vigneau C, Macher MA, Hourmant M, Legendre C. Gaillard F, et al. Among authors: garrouste c. Nephrol Dial Transplant. 2021 Mar 29;36(4):730-738. doi: 10.1093/ndt/gfz229. Nephrol Dial Transplant. 2021. PMID: 31778191
BACKGROUND: Long-term studies have demonstrated a slight increased risk for end-stage renal disease (ESRD) for living kidney donors (LKD). ...
BACKGROUND: Long-term studies have demonstrated a slight increased risk for end-stage renal disease (ESRD) for living kidney donors ( …
Outcomes of Older Patients (≥60 years) with New-Onset Idiopathic Nephrotic Syndrome Receiving Immunosuppressive Regimen: A Multicentre Study of 116 Patients.
Colliou E, Karras A, Boffa JJ, Ribes D, Garrouste C, Quintrec ML, Daugas E, Huart A, Ducloux D, Hummel A, Ferrandiz I, Demoulin N, Jourde-Chiche N, Chauveau D, Audard V, Faguer S. Colliou E, et al. Among authors: garrouste c. J Clin Med. 2019 Mar 2;8(3):298. doi: 10.3390/jcm8030298. J Clin Med. 2019. PMID: 30832362 Free PMC article.
Alternative immunosuppressive regimens, including B-cells depleting agents as frontline therapy, should be tested in this subset of patients to improve the mid- to long-term outcomes....
Alternative immunosuppressive regimens, including B-cells depleting agents as frontline therapy, should be tested in this subset of patients …
Evolution of chronic kidney disease after surgical aortic valve replacement or transcatheter aortic valve implantation.
Reuillard A, Garrouste C, Pereira B, Azarnoush K, Souteyrand G, Aniort J, Innorta A, Clerfond G, Heng AE, Eschalier R, Motreff P, Combaret N. Reuillard A, et al. Among authors: garrouste c. Arch Cardiovasc Dis. 2019 Mar;112(3):162-170. doi: 10.1016/j.acvd.2018.10.003. Epub 2019 Jan 14. Arch Cardiovasc Dis. 2019. PMID: 30655226 Free article.
BACKGROUND: Immediate improvement in kidney function has been reported after surgical aortic valve replacement or transcatheter aortic valve implantation. Long-term data, however, are not available. AIM: To assess the evolution of kidney function in chronic kidney disease …
BACKGROUND: Immediate improvement in kidney function has been reported after surgical aortic valve replacement or transcatheter aortic valve …
Ischemia reperfusion injury in kidney transplantation: A case report.
Philipponnet C, Aniort J, Garrouste C, Kemeny JL, Heng AE. Philipponnet C, et al. Among authors: garrouste c. Medicine (Baltimore). 2018 Dec;97(52):e13650. doi: 10.1097/MD.0000000000013650. Medicine (Baltimore). 2018. PMID: 30593134 Free PMC article.
Ischemia- reperfusion injury (IRI) is an evitable event after deceased donor transplantation and influences short term and long term graft outcome. Few data on IRI's histology in the setting of kidney transplantation are available in the literature despite its frequ …
Ischemia- reperfusion injury (IRI) is an evitable event after deceased donor transplantation and influences short term and long te …
16 results